Renal Cell Carcinoma
📧 Sign up to get email alerts when something new happens for Renal Cell Carcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-11-12Clinical Trial Update: Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc) [Phase 2]
Phase 2 study evaluating NKT2152 in combination with palbociclib and sasanlimab for advanced clear cell renal cell carcinoma has been termin…
-
CLINICAL_TRIALS research · 2025-11-12Clinical Trial Update: Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer [Phase 2]
Phase 2 trial evaluating radiotherapy in combination with a checkpoint inhibitor for metastatic renal cell carcinoma is currently recruiting…
-
CLINICAL_TRIALS withdrawal · 2025-11-12Clinical Trial Update: A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma [Phase 1, Phase 2]
This clinical trial update reports the termination of a Phase 1/2 study of NKT2152, a HIF2α inhibitor, in patients with advanced clear cell …
-
CLINICAL_TRIALS trial_result · 2025-11-12Clinical Trial Update: PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer [NA]
PROMOTE is a UCSF-sponsored clinical trial aiming to identify predictive markers of response in genitourinary cancers, including prostate ca…
-
CLINICAL_TRIALS research · 2025-11-12Clinical Trial Update: Reduction of Allogenic Blood Transfusion in Locally Advanced Kidney Cancer [NA]
Clinical trial update from Vanderbilt University Medical Center on reducing allogeneic blood transfusions in locally advanced renal cell car…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-11-10Clinical Trial Update: A Pilot Study of Blood-based Biomarkers for Response to Immune Checkpoint Inhibitors
A pilot clinical trial update evaluating blood-based biomarkers to predict response to immune checkpoint inhibitors in non-small cell lung c…
-
CLINICAL_TRIALS trial_result · 2025-11-10Clinical Trial Update: Dynamic Contrast Enhancement Computed Tomography for Evaluating Tumor Perfusion in Patients With Metastatic Renal Cell Carcinoma Receiving Targeted Therapies: Renal Cell Carcinoma (RCC) Scramble [Phase 3]
Phase 3 clinical trial update evaluating dynamic contrast-enhanced CT to evaluate tumor perfusion in metastatic renal cell carcinoma patient…
-
CLINICAL_TRIALS trial_result · 2025-11-06Clinical Trial Update: Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients
A clinical trial update reporting real-world outcomes of two combination therapies—nivolumab+ipilimumab and pembrolizumab+lenvatinib—in US p…
-
CLINICAL_TRIALS research · 2025-11-06Clinical Trial Update: Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab [Phase 1, Phase 2]
Clinical trial update for ARRY-614 in combination with nivolumab or nivolumab plus ipilimumab (Phase 1/2) currently active and not recruitin…
-
CLINICAL_TRIALS research · 2025-11-06Clinical Trial Update: Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in Cancer [Phase 1]
Phase 1 clinical trial evaluating the combination of low-dose-rate brachytherapy with immune checkpoint inhibitors in cancer; the study incl…
-
CLINICAL_TRIALS trial_result · 2025-10-30Clinical Trial Update: A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC) [Phase 1]
Phase 1 study evaluating APX005M in combination with nivolumab and ipilimumab in treatment-naïve patients with advanced melanoma or renal ce…
-
FDA approval · 2025-10-30FDA Approved: EVEROLIMUS — Original Application (Novugen Pharma (USA) LLC.)
FDA approved a generic version of Everolimus from Novugen Pharma (USA) LLC under an Original Application (ANDA).
-
CLINICAL_TRIALS trial_result · 2025-10-29Clinical Trial Update: Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma [Phase 1, Phase 2]
Phase 1/2 clinical trial update evaluating the combination of nivolumab and axitinib in patients with advanced renal cell carcinoma.
-
EMA approval · 2025-10-28EMA Authorised: Votrient (pazopanib) — Novartis Europharm Limited
The EMA authorised pazopanib (Votrient) for renal cell carcinoma in the European Union. The Marketing Authorization Holder is Novartis Europ…
-
CLINICAL_TRIALS research · 2025-10-28Clinical Trial Update: SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Clinical trial SYNERGY-AI is an AI-based precision oncology matching and registry study sponsored by Massive Bio, currently recruiting acros…
-
CLINICAL_TRIALS research · 2025-10-27Clinical Trial Update: Spontaneous Regression in Metastatic Melanoma and Renal Cell Carcinoma
The clinical trial update reports that the study on spontaneous regression in metastatic melanoma and renal cell carcinoma remains active bu…
-
CLINICAL_TRIALS research · 2025-10-24Clinical Trial Update: NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy [Phase 1]
A Phase 1 trial evaluating NBTXR3 activated by radiotherapy in combination with anti-PD-1 therapy for patients with advanced cancers; the st…
-
CLINICAL_TRIALS trial_result · 2025-10-22Clinical Trial Update: A Study of HFB301001 in Adult Patients With Advanced Solid Tumors [Phase 1]
The Phase 1 trial of HFB301001 in adults with advanced solid tumors has been terminated.
-
CLINICAL_TRIALS research · 2025-10-21Clinical Trial Update: Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC) [Phase 2]
Phase 2 clinical trial evaluating molecular residual disease-guided adjuvant therapy in renal cell carcinoma; currently recruiting.
-
CLINICAL_TRIALS trial_result · 2025-10-20Clinical Trial Update: Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC [Phase 2]
A Phase 2 study of PULSAR-ICI with or without IMSA101 in patients with oligometastatic non-small cell lung cancer and renal cell carcinoma w…
-
CLINICAL_TRIALS research · 2025-10-20Clinical Trial Update: RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy [Phase 2]
A Phase 2 clinical trial update evaluating RP2 in combination with tivozanib for metastatic renal cell carcinoma after progression on immuno…
-
CLINICAL_TRIALS trial_result · 2025-10-14Clinical Trial Update: A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors [Phase 1]
This Phase 1 trial update reports on the combination of MGC018 and MGD019 in participants with advanced solid tumors, including castration-r…
-
CLINICAL_TRIALS research · 2025-10-14Clinical Trial Update: Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies [Phase 1]
A Phase 1 study of JANX008 in advanced or metastatic solid tumors is currently recruiting, evaluating multiple indications including Non-Sma…
-
CLINICAL_TRIALS trial_result · 2025-10-10Clinical Trial Update: A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC) [Phase 2]
Phase 2 trial comparing treatments for translocation renal cell carcinoma (tRCC), including metastatic, unresectable, and AJCC Stage III/IV …
-
CLINICAL_TRIALS research · 2025-10-10Clinical Trial Update: Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC) [Phase 2]
A Phase 2 clinical trial is evaluating sequential cabozantinib therapy for advanced renal cell carcinoma; the study is currently recruiting.